Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 155.23

+8.4%

2:16 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tom pope who wrote (553)	3/24/2000 10:41:00 PM
From: aknahow	Read Replies (1) of 1834

Thanks. Agree the information came from here, but not sure the conclusion reached was exactly the same. When one says: "The average technology value (market cap minus cash [and cash equivalents]) is $7.2M per employee. That value has more than quadrupled since December 1996, when the average technology value per employee for 100 biotech companies was $1.6M." is that not the same as saying if the price of a stock goes up 4 times from a point in time when no change in the company has occurred it has by definition quadrupled it value employee ratio, its building value ratio, its pencil and pen ratio. Sounds impressive but not really that meaningful unless one believes that the number of employees rather than sales, earnings, patents. clinical trials is a good measure of value. Again thanks.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next